...
首页> 外文期刊>Cell death & disease. >Combination therapy targeting ectopic ATP synthase and 26S proteasome induces ER stress in breast cancer cells
【24h】

Combination therapy targeting ectopic ATP synthase and 26S proteasome induces ER stress in breast cancer cells

机译:靶向异位ATP合酶和26S蛋白酶体的联合疗法诱导乳腺癌细胞内质网应激

获取原文
           

摘要

F 1 F o ATP synthase is present in all organisms and is predominantly located on the inner membrane of mitochondria in eukaryotic cells. The present study demonstrated that ATP synthase and electron transport chain complexes were ectopically expressed on the surface of breast cancer cells and could serve as a potent anticancer target. We investigated the anticancer effects of the ATP synthase inhibitor citreoviridin on breast cancer cells through proteomic approaches and revealed that differentially expressed proteins in cell cycle regulation and in the unfolded protein response were functionally enriched. We showed that citreoviridin triggered PERK-mediated eIF2 α phosphorylation, which in turn attenuated general protein synthesis and led to cell cycle arrest in the G 0 /G 1 phase. We further showed that the combination of citreoviridin and the 26S proteasome inhibitor bortezomib could improve the anticancer activity by enhancing ER stress, by ameliorating citreoviridin-caused cyclin D 3 compensation, and by contributing to CDK1 deactivation and PCNA downregulation. More interestingly, the combined treatment triggered lethality through unusual non-apoptotic caspase- and autophagy-independent cell death with a cytoplasmic vacuolization phenotype. The results imply that by boosting ER stress, the combination of ATP synthase inhibitor citreoviridin and 26S proteasome inhibitor bortezomib could potentially be an effective therapeutic strategy against breast cancer.
机译:F 1 F o ATP合酶存在于所有生物中,主要位于真核细胞线粒体的内膜上。本研究表明,ATP合酶和电子传输链复合物在乳腺癌细胞表面异位表达,并且可以作为有效的抗癌靶标。我们通过蛋白质组学方法研究了ATP合酶抑制剂citreoviridin对乳腺癌细胞的抗癌作用,并揭示了在细胞周期调控和未折叠的蛋白质应答中差异表达的蛋白质在功能上得到了丰富。我们表明,citreoviridin触发PERK介导的eIF2α磷酸化,进而削弱了一般蛋白质的合成,并导致细胞周期停滞在G 0 / G 1期。我们进一步表明,柑桔维他汀和26S蛋白酶体抑制剂硼替佐米的组合可通过增强ER应激,改善柑桔维他汀引起的细胞周期蛋白D 3补偿以及促进CDK1失活和PCNA下调来改善抗癌活性。更有趣的是,联合治疗通过具有细胞质空泡表型的异常非凋亡caspase和自噬依赖性细胞死亡触发致死性。结果表明,通过增强内质网应激,ATP合酶抑制剂citreoviridin和26S蛋白酶体抑制剂硼替佐米的组合可能是一种有效的乳腺癌治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号